The lysis of allogeneic target cells by cytotoxic thymus-derived lymphocytes (CTL) was reduced markedly (20 to 100%) by an irreversible protease inhibitor, Nα-tosyl-L-lysyl-chloromethylketone (TLCK), at 0.2 to 2.0 × 10-4 M. Pretreatment of CTL and target cells indicated that TLCK affected primarily CTL, although it also decreased slightly the susceptibility of the target cells. At concentrations where TLCK blocked CTL lytic activity completely, it had no effect on the viability of the effector cell population as measured by 51Cr-label retention. In addition, the CTL treated with TLCK gradually recovered the cytotoxic activity after 1 to 4 days, suggesting that TLCK-modified components were replaced. Nε-acetyl-TLCK and Nε-succinyl-TLCK were synthesized, and they and 20 other protease inhibitors were also tested. Seventeen of the inhibitors did not block CTL activity. Whether the others had any effect could not be determined, because there was only a small difference in the concentrations at which they inhibited the cytotoxic reaction and at which they were toxic for the CTL. The overall results suggest that among the 23 inhibitors tested, TLCK was unique: it affects an unknown component, not necessarily a protease, required for cytotoxic activity of CTL. Addition of TLCK at different steps of the cytolytic sequence (conjugate formation, programming for lysis, and CTL-independent cell lysis) suggested that it affected programming for lysis, not the other steps.